.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Chinese Patent Office
Daiichi Sankyo
Moodys
Citi
Fuji
Mallinckrodt
Healthtrust
Boehringer Ingelheim
Queensland Health

Generated: November 22, 2017

DrugPatentWatch Database Preview

Acetaminophen; oxycodone hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for acetaminophen; oxycodone hydrochloride and what is the scope of acetaminophen; oxycodone hydrochloride freedom to operate?

Acetaminophen; oxycodone hydrochloride
is the generic ingredient in twelve branded drugs marketed by Actavis Elizabeth, Vintage Pharms Llc, West-ward Pharms Int, Barr, Vintage Pharms, Novel Labs Inc, Mikart, Bristol Myers Squibb, Mutual Pharm, Ascent Pharms Inc, Mallinckrodt Inc, Lannett Holdings Inc, Watson Labs, Sun Pharm Inds Inc, Mallinckrodt, Ortho Mcneil Pharm, Roxane, Aurolife Pharma Llc, Duramed Pharms Barr, Cerovene Inc, Alvogen Malta, Amneal Pharms, Mayne Pharma Inc, Amneal Pharms Ny, Rhodes Pharms, Janssen Pharms, and Halsey, and is included in fifty-six NDAs. There are thirteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Acetaminophen; oxycodone hydrochloride has forty-eight patent family members in nineteen countries.

There are sixty-six drug master file entries for acetaminophen; oxycodone hydrochloride. Fifty-one suppliers are listed for this compound.

Summary for acetaminophen; oxycodone hydrochloride

Pharmacology for acetaminophen; oxycodone hydrochloride

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vintage Pharms Llc
PERCOCET
acetaminophen; oxycodone hydrochloride
TABLET;ORAL085106-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Aurolife Pharma Llc
OXYCODONE AND ACETAMINOPHEN
acetaminophen; oxycodone hydrochloride
TABLET;ORAL201972-003Jul 15, 2013AARXNoNo► Subscribe► Subscribe► Subscribe
Mallinckrodt Inc
XARTEMIS XR
acetaminophen; oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL204031-001Mar 11, 2014DISCNYesNo► Subscribe► Subscribe► Subscribe
Mayne Pharma Inc
OXYCODONE AND ACETAMINOPHEN
acetaminophen; oxycodone hydrochloride
TABLET;ORAL090177-004Oct 20, 2008AARXNoNo► Subscribe► Subscribe► Subscribe
Mallinckrodt Inc
XARTEMIS XR
acetaminophen; oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL204031-001Mar 11, 2014DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Watson Labs
OXYCODONE AND ACETAMINOPHEN
acetaminophen; oxycodone hydrochloride
TABLET;ORAL040535-001Sep 5, 2003AARXNoNo► Subscribe► Subscribe► Subscribe
Barr
OXYCODONE AND ACETAMINOPHEN
acetaminophen; oxycodone hydrochloride
TABLET;ORAL087406-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Vintage Pharms
OXYCODONE AND ACETAMINOPHEN
acetaminophen; oxycodone hydrochloride
TABLET;ORAL090734-001Jul 11, 2013AARXNoNo► Subscribe► Subscribe► Subscribe
Mallinckrodt
OXYCODONE AND ACETAMINOPHEN
acetaminophen; oxycodone hydrochloride
TABLET;ORAL040550-002Jun 30, 2004DISCNNoNo► Subscribe► Subscribe► Subscribe
Lannett Holdings Inc
OXYCODONE AND ACETAMINOPHEN
acetaminophen; oxycodone hydrochloride
TABLET;ORAL207333-001Sep 25, 2017AARXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: acetaminophen; oxycodone hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,198,861Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans► Subscribe
8,790,694Gastric retentive extended release pharmaceutical compositions► Subscribe
9,539,328Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia► Subscribe
9,629,837Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia► Subscribe
9,433,582Gastric retentive extended release pharmaceutical compositions► Subscribe
8,858,963Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: acetaminophen; oxycodone hydrochloride

Country Document Number Estimated Expiration
Japan5897036► Subscribe
World Intellectual Property Organization (WIPO)2009114648► Subscribe
European Patent Office1294363► Subscribe
South Korea20140021992► Subscribe
Germany60101581► Subscribe
Denmark1294363► Subscribe
Australia2001239893► Subscribe
South Korea20030023876► Subscribe
Portugal1294363► Subscribe
Australia3989301► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Citi
Fish and Richardson
Daiichi Sankyo
AstraZeneca
Teva
McKesson
Fuji
US Department of Justice
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot